Clinica Chimica Acta:使用一种新的指数来预测原发性肝癌切除后的总生存率

2020-02-18 MedSci MedSci原创

目前,国际上已经有几种肝癌的分期和评分系统不能准确预测原发性肝癌切除后的总生存率。因此,本研究试图通过构建a指数及其相关的nomogram来克服这一局限性。

目前,国际上已经有几种肝癌的分期和评分系统不能准确预测原发性肝癌切除后的总生存率。因此,本研究试图通过构建a指数及其相关的nomogram来克服这一局限性。

研究人员选取了20071月至20152月在温州医科大学第一附属医院行根治性切除的672例患者。这些受试者按照7:3的比例随机分为训练组(n = 470)和验证组(n = 202)

研究人员在训练队列中使用包括A指数(由100××天冬氨酸转氨酶/白蛋白/白蛋白计算)在内的八个独立的危险因素制备了列线图。 训练集和验证集的列线图的一致性指数(C指数)在指示OS率方面相似。 诺模图显示了1年,3年和5OS的最强预测能力,ROC曲线下的面积分别为0.81820.78920.7669 校正曲线显示两组均具有一致的性能,Kaplan-Meier曲线分层显着(P <0.001),决策曲线分析(DCA)考虑到临床效果显示列线图的优越性。

研究表明,结合OSA指数的列线图的预测能力是最佳的。

原始出处:

Bin-Bin CaiXiang-Qing HouUse of a novel index, the A-index, and its associated nomogram to predict overall survival rates after resection of primary hepatocellular carcinoma

本文系梅斯医学(MedSci)原创编译整理,转载需授权!


版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1846856, encodeId=764b18468569e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 10 17:53:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849851, encodeId=44b3184985195, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Oct 23 11:53:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256749, encodeId=39931256e49f9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257495, encodeId=4760125e49591, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040261, encodeId=b99b1040261a1, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Feb 18 12:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1846856, encodeId=764b18468569e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 10 17:53:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849851, encodeId=44b3184985195, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Oct 23 11:53:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256749, encodeId=39931256e49f9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257495, encodeId=4760125e49591, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040261, encodeId=b99b1040261a1, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Feb 18 12:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=)]
    2020-10-23 windight
  3. [GetPortalCommentsPageByObjectIdResponse(id=1846856, encodeId=764b18468569e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 10 17:53:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849851, encodeId=44b3184985195, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Oct 23 11:53:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256749, encodeId=39931256e49f9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257495, encodeId=4760125e49591, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040261, encodeId=b99b1040261a1, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Feb 18 12:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1846856, encodeId=764b18468569e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 10 17:53:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849851, encodeId=44b3184985195, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Oct 23 11:53:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256749, encodeId=39931256e49f9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257495, encodeId=4760125e49591, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040261, encodeId=b99b1040261a1, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Feb 18 12:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1846856, encodeId=764b18468569e, content=<a href='/topic/show?id=d3a33e0306d' target=_blank style='color:#2F92EE;'>#原发性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37030, encryptionId=d3a33e0306d, topicName=原发性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=8e4c53, createdName=jiyangfei, createdTime=Tue Mar 10 17:53:00 CST 2020, time=2020-03-10, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1849851, encodeId=44b3184985195, content=<a href='/topic/show?id=61815385aa' target=_blank style='color:#2F92EE;'>#CTA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5385, encryptionId=61815385aa, topicName=CTA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ec9955, createdName=windight, createdTime=Fri Oct 23 11:53:00 CST 2020, time=2020-10-23, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1256749, encodeId=39931256e49f9, content=<a href='/topic/show?id=43706900963' target=_blank style='color:#2F92EE;'>#生存率#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=41, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=69009, encryptionId=43706900963, topicName=生存率)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6a6043, createdName=guoyibin, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1257495, encodeId=4760125e49591, content=<a href='/topic/show?id=df433e09082' target=_blank style='color:#2F92EE;'>#原发性肝癌#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=47, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=37090, encryptionId=df433e09082, topicName=原发性肝癌)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 20 00:53:00 CST 2020, time=2020-02-20, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1040261, encodeId=b99b1040261a1, content=肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Tue Feb 18 12:53:00 CST 2020, time=2020-02-18, status=1, ipAttribution=)]
    2020-02-18 留走人康

    肝癌,接下来就要细分了,对于体质好的病人,能否将PD-1类+抗血管新生+放疗等相结合,甚至有必要用TACE进行减负

    0

相关资讯

Nat Commun:原发性肝癌肺转移存在骤变拐点, CALML3基因可抑制肝癌生长和肺转移

近期,复旦大学附属中山医院肝肿瘤内科夏景林教授与中科院细胞生化所陈洛南研究员课题组进行合作,首次成功鉴定肝癌肺转移发生前的临界阶段,发现原发性肝癌肺转移存在骤变拐点,并首次报道了钙离子传导蛋白(calmodulin-like-protein,简称CALML3)可抑制肝癌生长和肺转移。相关研究成果以“Dynamic network biomarker indicates pulmonary meta

《CSCO原发性肝癌诊疗指南》解读

《CSCO原发性肝癌诊疗指南》发布,为中国肝癌诊治及研究提供了权威的临床实践依据和重要参考。

陈敏山:2019年原发性肝癌治疗进展盘点

陈敏山 教授,主任医师,博士生导师。现为中山大学肿瘤防治中心肝脏外科主任、中山大学肝癌研究所所长。兼任中国抗癌协会肝癌专业委员会候任主任委员、中国医师协会肝癌专业委员会副主任委员;广东省医学会肝癌分会主任委员、广东省抗癌协会肝癌专业委员会名誉主任委员、香港中文大学求佳外科客座教授。 从事肝癌的临床和研究工作30年,临床上以外科为主,熟悉和掌握肝癌多种治疗手段,并积极推广肝癌的多学科综合

曾昭冲教授:迈向精准、联合的未来——原发性肝癌放疗新近进展

由于影像学和现代放疗设备的结合,肿瘤的精确放疗日新月异,精确放疗设备也越来越普及。近年来,有关原发性肝癌精确放疗的临床研究结果显示,放疗作为原发性肝癌综合治疗的一部分,能提高肝癌患者的生存获益。放眼最近几年原发性肝癌放疗进展,主要体现在小肝癌的立体定向放疗和门静脉癌栓的综合治疗两方面。

原发性肝癌诊疗规范(2019年版)

原发性肝癌是目前我国第4位常见恶性肿瘤及第2位肿瘤致死病因,严重威胁我国人民的生命和健康。原发性肝癌主要包括肝细胞癌(Hepatocellular carcinoma,HCC)、肝内胆管癌(Intrahepatic cholangiocarcinoma,ICC)和HCC-ICC混合型3种不同病理学类型,3者在发病机制、生物学行为、组织学形态、治疗方法以及预后等方面差异较大,其中HCC占85%~90

原发性肝癌放疗的指南推荐解读

基于循证医学证据的治疗指南为临床肿瘤医生提供了较为合理的治疗策略推荐。目前,巴塞罗那临床肝癌(BCLC)、欧洲肝病研究学会及欧洲癌症治疗研究组织(EASL⁃EORTC)、美国肝病研究学会(AASLD)、美国国家综合癌症网络(NCCN)、亚太地区原发性肝癌专家(APPLE)、韩国肝癌研究组及国立癌症中心(KLCSG⁃NCC)和中华医学会放射肿瘤治疗学分会(CSTRO)等国内外多个组织均发布了原发性肝